Phacilitate Leaders World 

What's Next for Commercial Cell Therapy Manufacturing?

What's Next for Commercial Cell Therapy Manufacturing?

Panellists from Invetech, Bluebird Bio, Juno Therapeutics and Hitachi Chemical Advanced Therapeutics Solutions (HCATS) discuss their vision for the coming era of industrialised cell therapy production at Phacilitate Leaders World 2019, Miami

Automation is at the heart of achieving efficiency and cost-effectiveness in cell therapy manufacturing; however, many companies face barriers when it comes to introducing automation.

Invetech hosted a panel discussion at Phacilitate Leaders World in Miami, with David Hodl opening the floor by highlighting that many cell therapy companies are still challenged with the ‘how’ and ‘when’, and not engaging automation from the very beginning because of funding limitations and process complexity.

“A common theme we hear is ‘We need to first get our therapy approved, and then we’ll consider automation later’. With the approval of Yescarta and Kymriah in 2018, that ‘later’ has suddenly become ‘now’.”

In addition to David, the panel comprised of Steve Goodman (bluebird bio), Brian Hampson (Hitachi Chemical Advanced Therapeutics Solutions) and Randy Schweickart (Juno Therapeutics) who discussed their vision for the coming era of industrialised cell therapy production.

You can watch the full discussion below.

  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman